Objective  To investigate the efficacy of edaravone and dexborneol combined with Xingnaojing in treating acute cerebral infarction (ACI) and to identify risk factors for poor patient outcomes.

Methods  ACI patients admitted to Pingyang Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University from January 2023 to December 2024 were selected and divided into a control group (treated with edaravone and dexborneol concentrated solution for injection) and a study group (treated with daravone and dexborneol concentrated solution for injection combined with Xingnaojing injection). The therapeutic effects and risk factors for poor prognosis after treatment were compared between the two groups.

Results  A total of 106 ACI patients were included, 53 in each group. The overall response rate in the study group was significantly higher than that in the control group (94.34% vs. 81.13%, P<0.05). After treatment, the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale scores were lower in the study group than in the control group, and the Barthel Index was higher than in the control group (P<0.05). Post-treatment serum neurological biochemical markers and vascular endothelial function parameters were better than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Logistic regression analysis revealed that the following factors constituted risk factors for poor prognosis in ACI patients following treatment: an admission NIHSS score >13, time from onset to thrombolysis >6 hours, and the presence of hypertension, diabetes mellitus, hyperlipidemia, coronary heart disease, a history of stroke, or a family history of stroke.

Conclusion  The combination of edaravone and dexborneol with Xingnaojing significantly enhances the clinical efficacy of ACI treatment, while improving patients' neurological function and vascular endothelial function. Concurrently, greater emphasis should be placed on addressing risk factors associated with poor prognosis following thrombolytic therapy for ACI.

1.Zhang R, Wei H, Ren Y, et al. Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China[J]. Front in Neurol, 2021, 12(1): 685454. DOI: 10.3389/fneur.2021.685454.

2.齐英斌, 许卓, 周艳, 等. 依达拉奉右莰醇对老年缺血性脑卒中患者脑细胞的保护作用[J]. 中国老年学杂志, 2024, 44(8): 2035-2037. [Qi YB, Xu Z, Zhou Y, et al. The protective effect of edaravone on brain cells in elderly patients with ischemic stroke[J]. Chinese Journal of Gerontology, 2024, 44(8): 2035-2037.] DOI: 10.3969/j.issn.1005-9202.2024.08.060.

3.巩俐, 刘雪梅, 陈宝鑫, 等. 中药注射液联合常规药物治疗卒中后认知障碍的网状Meta分析[J]. 药物评价研究, 2025, 48(2): 510-525. [Gong L, Liu XM, Chen BX, et al. Network Meta-analysis of Chinese medicine injection combined with conventional drugs for post-stroke cognitive impairment[J]. Drug Evaluation Research, 2025, 48(2): 510-525.] DOI: 10.7501/j.issn.1674-6376.2025.02.023.

4.Wang J, Zhao M, Qiao Y, et al. Neurological deterioration after acute ischemic stroke: a common phenomenon with important implications[J]. Cerebrovasc Dis, 2025, 24(1): 21-27. DOI: 10.1159/000543763. 

5.郭飞, 黄云慧, 黄宇靖, 等. 醒脑静注射液联合阿替普酶治疗缺血性脑卒中疗效和安全性的系统评价[J]. 实用医学杂志, 2022, 38(2): 206-211. [Guo F, Huang YH, Huang JY, et al. Systematic review of efficacy and safety of Xingnaojing injection combined with alteplase for ischemic stroke[J]. The Journal of Practical Medicine, 2022, 38(2): 206-211.] DOI: 10.3969/j.issn.1006-5725.2022.02.015.

6.杨卫丽, 耿君杰. 醒脑静注射液联合依达拉奉右莰醇治疗急性后循环脑梗死静脉溶栓患者的效果[J]. 中国民康医学, 2023, 35(19): 41-43. [Yang WL, Geng JJ. Effects of Xingnaojing injection combined with edaravone in treatment of acute posterior circulation cerebral infarction patients with intravenous thrombolysis[J]. Medical Journal of Chinese People's Health, 2023, 35(19): 41-43.] DOI: 10.3969/j.issn.1672-0369.2023.19.013.

7.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. [Chinese Medical Association Neurology Branch, Chinese Medical Association Neurology Branch Cerebrovascular Disease Group. Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9): 666-682.] DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

8.薛芳, 张永林, 张继萍, 等. 脑栓通胶囊联合丁苯酞注射液治疗急性脑梗死的疗效及对血流动力学影响[J]. 中华中医药学刊, 2022, 40(2): 215-218. [Xue F, Zhang YL, Zhang JP, et al. Effect of Naoshuantong capsule combined with butylphthalide injection on acute cerebral infarction and its effect on hemodynamics[J]. Chinese Archives of Traditional Chinese Medicine, 2022, 40 (2): 215-218.] DOI: 10.13193/j.issn.1673-7717.2022.02.050.

9.黄坚红, 才鼎, 卞金玲, 等. 脑心清片治疗缺血性脑卒中恢复期多中心随机双盲对照研究[J]. 中国中西医结合杂志, 2022, 42(7): 802-810. [Huang JH, Cai D, Bian JL, et al. Effect of Naoxinqing tablet in the treatment of convalescent stroke:a multicenter, randomized, double-blind,control trial[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2022, 42(7): 802-810.] DOI: 10.7661/j.cjim.20220328.012.

10.刘前, 邓倩, 周静, 等. 依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J]. 中国老年学杂志, 2023, 43(2): 276-279. [Liu Q, Deng Q, Zhou J, et al. Clinical efficacy and effects on cerebral haemodynamics of edaravone combined with atorvastatin in the treatment of acute cerebral infarction in the elderly[J]. Chinese Journal of Gerontology, 2023, 43(2): 276-279.] DOI: 10.3969/j.issn.1005-9202.2022.02.006.

11.陈文博, 陈锐, 唐妍妍, 等. 醒脑静注射液联合依达拉奉注射液治疗急性脑出血的有效性的Meta分析[J]. 中国医院用药评价与分析, 2025, 25(1): 76-80. [Chen WB, Chen R, Tang  YY, et al. Meta-analysis of the efficacy of Xingnaojing injection combined with edaravone injection in the treatment of acute intracerebral haemorrhage[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2025, 25(1): 76-80.] DOI: 10.14009/j.issn.1672-2124.2025.01.017.

12.代露. 依达拉奉联合醒脑静注射液治疗脑出血的临床效果及对神经细胞因子和炎性反应递质的影响[J]. 中外医药研究, 2024, 3(4): 95-97. [Dai L. Clinical effect of edaravone combined with xingnaojing injection in the treatment of cerebral hemorrhage and its effect on neurocytokines and inflammatory response transmitters[J]. Journal of Chinese and Foreign Medicine and Pharmacy Research, 2024, 3(4): 95-97.] DOI: 10.3969/j.issn.2096-6229.2024.04.032.

13.Wang XX, Wang F, Mao GH, et al. NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke[J]. Acta Pharmacol Sin, 2021, 43 (3): 529-540. DOI: 10.1038/s41401-021-00705-5. 

14.Amirshahrokhi K, Imani M. Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2/HO-1 and inhibition of NF-κB, iNOS/NO and inflammatory cytokines[J]. Mol Biol Rep, 2025, 52(1): 222. DOI: 10.1007/s11033-025-10343-3.

15.张岳. 丁苯酞联合阿替普酶治疗缺血性ACI的近期疗效及其预后影响因素Logistic回归分析[J]. 临床合理用药, 2025, 18(9): 22-26. [Zhang Y. Short-term efficacy of butylphthalide combined with alteplase in the treatment of ischemic ACI and its prognostic influencing factors by logistic regression analysis[J]. Chinese Journal of Clinical Rational Drug Use, 2025, 18(9): 22-26.] DOI: 10.15887/j.cnki.13-1389/r.2025.09.006.

16.孙青, 周小燕. 发病3小时内阿替普酶溶栓可改善急性脑梗死患者的预后[J]. 内科急危重症杂志, 2024, 30(6): 550-553. [Sun Q, Zhou XY. Thrombolysis with alteplase within 3 hours of onset improves outcomes in patients with acute ischaemic stroke[J]. Journal of Internal Medicine and Critical Care, 2024, 30(6): 550-553.] DOI: 10.11768/nkjwzzzz20240614.

17.洪波, 谷亚伟, 王利军, 等. 小剂量rt-PA静脉溶栓联合依达拉奉右莰醇治疗高龄中重度急性缺血性脑卒中的时机研究[J]. 中国慢性病预防与控制, 2024, 32(7): 514-517. [Hong  B, Gu YW, Wang LJ, et al. The timing of low-dose rt-PA intravenous thrombolysis combined with edaravone dexborneol in the elderly patients with moderate to severe acute ischemic stroke[J]. Chinese Journal of Prevention and Control of Chronic Diseases, 2024, 32(7): 514-517.] DOI: 10.16386/j.cjpccd.issn.1004-6194.2024.07.007.

18.Jia J, Wang L, Zhang L, et al. Analysis of the expression levels of chemerin, ox-LDL, MMP-9, and PAPP-A in ICVD patients and their relationship with the severity of neurological impairment[J]. Brain Behav, 2022, 12(7): 2613. DOI: 10.1002/brb3.2613.

19.时蕴琦, 江春. 急性脑梗死病人短期预后的影响因素[J]. 中西医结合心脑血管病杂志, 2025, 23(7): 1098-1101. [Shi  WQ, Jiang C. Short-term efficacy of butylphthalide combined with alteplase in the treatment of ischemic ACI and its prognostic influencing factors by logistic regression analysis[J]. Chinese Journal of Clinical Rational Drug Use, 2025, 23(7): 1098-1101.] DOI: 10.12102/j.issn.1672-1349.2025.07.024.